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Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that
the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a
downstream target of class III phosphoinositide 3-kinase
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Richard WARD‡, Darren CROSS‡, Ian G. GANLEY* and Dario R. ALESSI*1
*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
†Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
‡Oncology iMED, AstraZeneca, Alderley Park, Cheshire SK10 4TG, U.K.
The Vps34 (vacuolar protein sorting 34) class III PI3K
(phosphoinositide 3-kinase) phosphorylates PtdIns (phos-
phatidylinositol) at endosomal membranes to generate PtdIns(3)P
that regulates membrane trafficking processes via its ability to
recruit a subset of proteins possessing PtdIns(3)P-binding PX
(phox homology) and FYVE domains. In the present study, we
describe a highly selective and potent inhibitor of Vps34, termed
VPS34-IN1, that inhibits Vps34 with 25 nM IC50 in vitro, but
does not significantly inhibit the activity of 340 protein kinases
or 25 lipid kinases tested that include all isoforms of class I
as well as class II PI3Ks. Administration of VPS34-IN1 to cells
induces a rapid dose-dependent dispersal of a specific PtdIns(3)P-
binding probe from endosome membranes, within 1 min, without
affecting the ability of class I PI3K to regulate Akt. Moreover,
we explored whether SGK3 (serum- and glucocorticoid-regulated
kinase-3), the only protein kinase known to interact specifically
with PtdIns(3)P via its N-terminal PX domain, might be
controlled by Vps34. Mutations disrupting PtdIns(3)P binding
ablated SGK3 kinase activity by suppressing phosphorylation of
the T-loop [PDK1 (phosphoinositide-dependent kinase 1) site]
and hydrophobic motif (mammalian target of rapamycin site)
residues. VPS34-IN1 induced a rapid ∼50–60% loss of SGK3
phosphorylation within 1 min. VPS34-IN1 did not inhibit activity
of the SGK2 isoform that does not possess a PtdIns(3)P-binding
PX domain. Furthermore, class I PI3K inhibitors (GDC-0941 and
BKM120) that do not inhibit Vps34 suppressed SGK3 activity by
∼40%. Combining VPS34-IN1 and GDC-0941 reduced SGK3
activity ∼80–90%. These data suggest SGK3 phosphorylation
and hence activity is controlled by two pools of PtdIns(3)P.
The first is produced through phosphorylation of PtdIns by
Vps34 at the endosome. The second is due to the conversion
of class I PI3K product, PtdIns(3,4,5)P3 into PtdIns(3)P, via
the sequential actions of the PtdIns 5-phosphatases [SHIP1/2
(Src homology 2-domain-containing inositol phosphatase 1/2)]
and PtdIns 4-phosphatase [INPP4B (inositol polyphosphate 4-
phosphatase type II)]. VPS34-IN1 will be a useful probe to
delineate physiological roles of the Vps34. Monitoring SGK3
phosphorylation and activity could be employed as a biomarker
of Vps34 activity, in an analogous manner by which Akt is used
to probe cellular class I PI3K activity. Combining class I (GDC-
0941) and class III (VPS34-IN1) PI3K inhibitors could be used as
a strategy to better analyse the roles and regulation of the elusive
class II PI3K.
Key words: mammalian target of rapamycin (mTOR), N-Myc
downstream-regulated gene-1 (NDRG1), phosphoinositide
3-kinase (PI3K), protein kinase inhibitor, signal transduction
inhibitor.
INTRODUCTION
PI3Ks (phosphoinositide 3-kinases) phosphorylate the 3′-position
hydroxy group of the D-myo-inositol head group of PtdIns
(phosphatidylinositol) to generate 3-phosphoinositides that are
critical in switching on downstream signalling pathways [1].
These orchestrate a wide range of biological responses including
controlling cell growth, proliferation and intracellular trafficking
[2,3]. Work in this area has taken on added urgency, as
it is now clear that understanding disruptions in diverse
PI3K signalling pathways lie at the centre of understanding
major diseases such as cancer, inflammation heart failure and
diabetes [4–6].
There are three different classes of PI3Ks termed class
I, class II and class III [7]. These enzymes act on most
cellular membranes. The most studied enzymes are the four
members of class I PI3Ks (p110α, p110β p110γ and p110δ)
that phosphorylate PtdIns(4,5)P2 at the plasma membrane to
generate the signalling second messenger PtdIns(3,4,5)P3 in
response to agonists that trigger activation of growth factors,
Ras or G-protein-coupled receptors [8]. PtdIns(3,4,5)P3, as
well as its immediate breakdown product PtdIns(3,4)P2, trigger
downstream signalling responses by interacting specifically
with a subgroup of signalling proteins that possess a PH
(pleckstrin homology) domain that bind with high affinity to
these 3-phosphoinositides [9]. One of the best characterized
Abbreviations: 4E-BP1, eukaryotic initiation factor 4E-binding protein 1; DMEM, Dulbecco’s modified Eagle’s medium; EEA1, early endosome antigen 1;
HRP, horseradish peroxidase; IGF, insulin-like growth factor; INPP4B, inositol polyphosphate 4-phosphatase type II; IP1, inositol phosphate; ITC, isothermal
titration calorimetry; mTOR, mammalian target of rapamycin; mTORC, mammalian target of rapamycin complex; NDRG1, N-Myc downstream-regulated
gene-1; PDK1, phosphoinositide-dependent kinase 1; PH, pleckstrin homology; PI3K, phosphoinositide 3-kinase; PRAS40, proline-rich Akt substrate 40
kDa; PtdIns, phosphatidylinositol; PX, Phox homology; SGK3, serum- and glucocorticoid-regulated kinase-3; SHIP1/2, Src homology 2-domain-containing
inositol phosphatase 1/2; TSC2, tuberous sclerosis complex 2; Vps34, vacuolar protein sorting 34; VSV-G, vesicular stomatitis virus glycoprotein.
1 Correspondence may be addressed to either of these authors (email r.bago@dundee.ac.uk or d.r.alessi@dundee.ac.uk).
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signalling pathways activated by class I PI3K proteins are
the Akt protein kinases that control critical processes such
as metabolism and growth by phosphorylating multiple targets
including FOXO (forkhead box O) transcription factors, TSC2
(tuberous sclerosis complex 2) and GSK3 (glycogen synthase
kinase 3) [10]. Following activation of class I PI3Ks, Akt and one
of its upstream protein kinases termed PDK1 (phosphoinositide-
dependent kinase 1) are recruited to the plasma membrane via
their PtdIns(3,4,5)P3/PtdIns(3,4)P2-binding PH domains. This
results in PDK1 phosphorylating the T-loop Thr308 residue thereby
partially activating Akt [11–14]. Akt is also phosphorylated by
mTORC2 (mammalian target of rapamycin complex-2) at Ser473
located within the hydrophobic motif at the C-terminal non-
catalytic region [15]. Phosphorylation of Ser473 also serves to
promote the phosphorylation of Akt at Thr308 by PDK1 [16].
PtdIns(3,4,5)P3 can then be converted into PtdIns(3)P via the
sequential actions of the PtdIns 5-phosphatases [SHIP1/2 (Src
homology 2-domain-containing inositol phosphatase 1/2)] [17]
and PtdIns 4-phosphatase [INPP4B (inositol polyphosphate 4-
phosphatase type II)] [18]. PtdIns(3)P is rapidly dephosphorylated
in cells to PtdIns by a family of myotubularin PtdIns 3-
phosphatases [19].
Class II and class III PI3Ks phosphorylate PtdIns to generate
PtdIns(3)P. The class II PI3K subfamily has three members in
vertebrates (PI3KC2α, PI3KC2β and PI3KC2γ ), but the roles that
these perform and how they are regulated are poorly understood
[20,21]. The single class III PI3K isoform termed Vps34 (vacuolar
protein sorting 34) play an important role in controlling vesicular
protein sorting, a phenomenon that was first discovered in yeast
[22]. In all eukaryotes, Vps34 forms a core complex with two
other protein subunits termed Vps15 (a serine/threonine protein
kinase) [23] and beclin-1 (also known as Vps30 or ATG6) [24].
This core complex then interacts with a growing list of proteins
to form distinct complexes controlling membrane endosomal
trafficking processes and endosome–lysosome maturation as well
as autophagy [25,26].
The most thoroughly characterized PtdIns(3)P-binding
domains are a subset of FYVE and PX (Phox homology) domains
[27–30]. There is a pool of PtdIns(3)P that is highly enriched on
early endosomes and in the internal vesicles of multivesicular
endosomes [31]. PtdIns(3)P-binding PX and FYVE domains
display relatively low PtdIns(3)P-binding affinity which, in
combination with high myotubularin PtdIns 3-phosphatase
activity, permits rapid and highly dynamic localization and
responses [25,29]. Consistent with a key role of Vps34 and
PtdIns(3)P in regulating vesicular trafficking, several proteins
containing PX and FYVE domains specific for PtdIns(3)P have
been identified that play critical roles in protein sorting pathways
[32].
In the present study, we characterize a Vps34 inhibitor termed
VPS34-IN1. We show that this compound inhibits recombinant
Vps34 with nanomolar potency, but does not significantly inhibit
other protein kinases or lipid kinases tested, including class I or
class II PI3Ks. We demonstrate that VPS34-IN1 rapidly reduces
endosomal PtdIns(3)P levels within 1 min of drug treatment.
Furthermore, we utilize VPS34-IN1 to demonstrate that Vps34
plays a role in regulating the phosphorylation and activity of the
SGK3 (serum- and glucocorticoid-regulated protein kinase-3),
which is the only protein kinase known to possess a selective
PtdIns(3)P-binding PX domain. Our data suggest that SGK3
activity is partially controlled by a pool of PtdIns(3)P, produced
via phosphorylation of PtdIns by Vps34 and another pool of
PtdIns(3)P that could be derived from dephosphorylation of
PtdIns(3,4,5)P3 to PtdIns(3)P through the sequential actions of
SHIP1/2 and INPP4B PtdIns phosphatases. VPS34-IN1 will be a
useful probe for defining the roles that the class III PI3K plays.
Moreover, analysing SGK3 phosphorylation and/or activity could
be used as a downstream biomarker for Vps34 activity in the
same way in which Akt phosphorylation is currently deployed to
monitor class I PI3K pathway.
MATERIALS AND METHODS
Materials
Protein G–Sepharose was from GE Healthcare. [γ -32P]ATP was
from PerkinElmer. Agarose-conjugated anti-FLAG M2 antibody,
Triton X-100, EDTA, EGTA, sodium orthovanadate, sodium
glycerophosphate, sodium fluoride, sodium pyrophosphate,
2-mercaptoethanol, sucrose, benzamidine, Tween 20, Tris/HCl,
sodium chloride, magnesium acetate and doxycyclin were from
Sigma. PMSF was from Melford. Tissue culture reagents,
Novex 4–12% Bis-Tris gels and NuPAGE LDS sample
buffer was from Invitrogen. Ampicillin was from Merck. P81
phosphocellulose paper was from Whatman. Methanol and
chloroform were from VWR Chemicals. Inhibitors GDC-0941
(Axon Medchem), GSK2334470 (Tocris), AZD8055 (Selleck)
and BKM120 (Chemie Tek) were purchased from the indicated
suppliers. VPS34-IN1 (1-[{2-[(2-chloropyridin-4yl)amino]-4′-
(cyclopropylmethyl)-[4,5′-bipyrimidin]-2′-yl}amino]-2-methyl-
propan-2-ol) was synthesized as described in patent WO
2012085815 A1 [Cornella Taracido, I., Harrington, E.M., Honda,
A. and Keaney, E. (2012) Preparation of bipyrimidinamine
derivatives for use as Vps34 inhibitors; method for synthesis
of this compound is described on page 73, Table 4, example
16a.VPS34-IN1 has a CAS registry number 1383716-33-3].
General methods
Recombinant DNA procedures were performed using standard
protocols. Mutagenesis was performed using the QuikChange
site-directed mutagenesis (Stratagene) with KOD polymerase
(Novagen). DNA constructs were purified from Escherichia
coli DH5α using a Maxi prep kit (Qiagen) according to the
manufacturer’s instructions. Verification of the constructs was
performed by the Sequencing Service (MRC Protein Phosphoryla-
tion Unit, College of Life Sciences, University of Dundee, U.K.;
http://www.dnaseq.co.uk). DNA for bacterial protein expression
was transformed into E. coli BL21-CodonPlus (DE3)-RIL
cells (Stratagene). All recombinant proteins generated for the
present study have an assigned [DU] number and are described
on the reagents website (https://mrcppureagents.dundee.ac.uk/).
Recombinant proteins used in the present study were as follows:
Vps34/15 [DU8692], GST–TAPP1-(195–315) [DU17323], GST–
Grp1-(241–399) [DU3464], GST–PLCδ-(1–178) [DU12981],
3×FLAG–SGK3-(1–162) wild-type [DU44877], 3×FLAG–
SGK3-(1–162) R50A [DU44923] and 3×FLAG–SGK3-(1–162)
R90A [DU44883].
Cell culture, transfection and cell lysis
U20S cell line was kindly provided by John Rouse (MRC
Protein Phosphorylation and Ubiquitylation Unit, University
of Dundee, Dundee, U.K.). Cells were cultured in DMEM
(Dulbecco’s modified Eagle’s medium) supplemented with 10%
(v/v) FBS, 2 mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml
streptomycin. cDNA for mouse Hrs (residues 147–223 ×2 joined
by a linker) were cloned into a pBABE.puro vector. The construct
was co-transfected into HEK (human embryonic kidney)-293FT
cells with GAG/POL and VSV-G (vesicular stomatitis virus
glycoprotein) expression plasmids (Clontech) for retrovirus
c© The Authors Journal compilation c© 2014 Biochemical Society
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production using Lipofectamine 2000 (Life Technologies) in
accordance with the manufacturers’ instructions. The virus was
harvested 48 h after transfection and applied to U20S cells in
the presence of 10 μg/ml polybrene. Cells were selected with
10 μg/ml puromycin before single cell colony selection to identify
low expression GFP–FYVEHrs clones. U2OS Flp/In cell line
was kindly provided by John Rouse. Cells were cultured in
McCoy medium supplemented with 10% (v/v) FBS, 2 mM
L-glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin.
Stable cell lines expressing doxycycline-inducible proteins were
generated using the Flp-InTM T-RExTM system (Invitrogen). Stable
transfected clones were selected using 0.01 mM hygromycin
in cell medium. Protein expression was induced by adding
0.01 mg/ml doxycycline in the medium for 24 h prior to cell lysis.
Inhibitor treatment was carried out as described in the Figure
legends. The cells were lysed in buffer containing 50 mM Tris/HCl
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
sodium orthovanadate, 10 mM sodium glycerophosphate, 50 mM
sodium fluoride, 10 mM sodium pyrophosphate, 0.27 M sucrose,
0.1% 2-mercaptoethanol, 1 mM benzamidine and 0.1 mM PMSF.
Lysates were clarified by centrifugation at 16000 g for 10 min at
4 ◦C. Protein concentration was calculated using Bradford assay
(Thermo Scientific). Immunoblotting and immunoprecipitation
were performed using standard procedures. The signal was
developed using the ECL Western Blotting Detection kit (GE
Healthcare) on Hyperfilm ECL film (GE Healthcare).
Antibodies
The following antibodies were raised in sheep, by the
DSTT (Division of Signal Transduction Therapy) at the
University of Dundee, and affinity-purified against the indicated
antigens: anti-Akt1 (S695B, third bleed; raised against
residues 466–480 of human Akt1: RPHFPQFSYSASGTA),
anti-PRAS40 (proline-rich Akt substrate 40 kDa) (S115B, first
bleed; raised against residues 238–256 of human PRAS40:
DLPRPRLNTSDFQKLKRKY), anti-(phospho-PRAS40 Thr246)
(S114B, second bleed; raised against residues 240–251 of
human PRAS40: CRPRLNTpSDFQK), anti-NDRG1 (N-Myc
downstream-regulated gene-1) (S276B third bleed; raised against
full-length human NDRG1) and anti-SGK3 [S037D second
bleed; raised against human SGK3 PX domain comprising
residues 1–130 of SGK3]. Anti-phospho-Akt Ser473 (9271), anti-
phospho-Akt Thr308 (4056), anti-phospho-NDRG1 Thr346 (5482),
anti-GAPDH (2118), anti-phospho-4E-BP1 (eukaryotic initiation
factor 4E-binding protein 1) Thr37/46 (9459), anti-phospho-4E-
BP1 S65 (9451), anti-4E-BP1 (9452) and anti-phospho-SGK3
Thr320 (5642) antibodies were purchased from Cell Signaling
Technology (note we found that this antibody did not recognize
T-loop of SGK1 or SGK2). Anti-(phospho-SGK hydrophobic
motif [Ser486 in SGK3]) antibody (sc16745) was from Santa Cruz
Biotechnology and total SGK1/2 antibody was from Sigma (5188)
as was the mouse anti-FLAG antibody. Secondary antibodies
coupled to HRP (horseradish peroxidase) were obtained from
Thermo Scientific.
In vitro Vps34 PI3K assay
The PI3K activity of recombinant Vps34–Vps15 complex
expressed in insect cells was assayed in vitro via a radioactive
liposome kinase assay. Liposomes were formed by extrusion
of crude liver PtdIns (Avanti Polar Lipids, 840042) through a
100 nm filter membrane and incubated with 50 ng of recombinant
Vps34/15 for 30 min at 1000 rev./min and 4 ◦C. Assay buffer
was 20 mM Tris/HCl, pH 7.4, 67 mM NaCl, 10 mM MnCl2,
0.02% CHAPS and 1 mM DTT in the presence of 5 μM
ATP and 3 μCi [γ -32P]ATP per reaction. Reactions were
terminated by the addition of 500 μl of chloroform/methanol/HCl
(100:200:3.5, by vol.) and subsequently 180 μl of chloroform
and 300 μl of 0.1 M HCl to phase split reactions. The lower
lipid-containing phase was retained and dried before the
addition of chloroform. Reactions were spotted on to a Silica
60 TLC plate [activated with 1% potassium oxalate, 5 mM
EDTA and 50% (v/v) methanol] and separated by a solvent
comprising methanol/chloroform/water/ammonium bicarbonate
(47:60:11.2:2, by vol.). Radioactive incorporation was analysed
by Fujifilm Image reader FLA-2000 and quantified by AIDA
image analysis, IC50 values were determined by non-linear
regression using Prism software.
AstraZeneca lipid kinase profiling
All compounds or DMSO for the PI4Kα, PI4Kβ, PIP5Kγ and
PI3Kα biochemical, and IP1 (inositol phosphate) cell-based,
assays were dispensed from source plates containing compounds
at 10 mM in 100% (v/v) DMSO or 100% DMSO, directly into
assay plates using an ECHO 555 Acoustic dispenser (LabcyteTM).
PI4Kα and PI4Kβ were assayed using the ADP-GloTM Kinase
Assay Kit (Promega), in Greiner 384-well white low-volume
plates in a 5 μl reaction volume consisting of 20 mM Bis-
Tris propane (pH 7.5), 10 mM MgCl2, 0.5 mM EGTA, 1 mM
DTT, 0.075 mM Triton X-100, 1.5% DMSO with or without
an inhibitor at varying concentrations, D-myo-PtdIns substrate
(Echelon Biosciences), ATP and purified enzyme. The PI4Kα
assay was performed with 1 nM PI4KCA (Millipore), 72 μM
ATP (KMappATP) and 25 μM PtdIns (KMappPI). The PI4Kβ
assay was performed with 2 nM PI4KCB (SignalChem), 220 μM
ATP (KMappATP) and 50 μM PtdIns (<KMappPI). The assay
was allowed to proceed for 45 min at ambient temperature before
stopping the reaction by the addition of 5 μl of ADP-Glo reagent.
Plates were then covered and incubated for 40 min at ambient
temperature. Kinase detection reagent (10 μl) was then added
and the plates were incubated for 30 min before the luminescence
signal was read with a PHERAstar plate reader (BMG Labtech).
PIP5Kγ assay was performed with the ADP-GloTM Kinase
Assay Kit (Promega) in Greiner 384-well white low-volume plates
in a 5 μl reaction volume consisting of 20 mM Bis-Tris propane
(pH 7.0), 10 mM MgCl2, 0.5 mM EGTA, 1 mM DTT, 0.024 mM
Triton X-100, 1.5% DMSO with or without an inhibitor at
varying concentrations, 14 μM D-myo-PIP (PtdIns 4-phosphate)
substrate [<KMappPI(4)P] (Echelon Biosciences), 20 μM ATP
(KMappATP) and PIP5K1C (expressed and purified by CRT,
used at a 1:750 dilution). Assay incubations, additions and reads
were performed as described for the PI4Kα and PI4Kβ ADP-Glo
assays.
The PI3Kα assay was performed using the Kinase-Glo®
Plus Luminescence Assay Kit (Promega) in Greiner 384-
well white low-volume plates. PIK3CA (expressed and
purified by AZ; 20 nM) in phosphorylation buffer consisting
of 50 mM Tris/HCl (pH 7.4), 0.05% CHAPSO {3-[(3-
cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesul-
fonic acid}, 10 mM MgCl2 and 2.1 mM DTT was pre-incubated
with or without an inhibitor at varying concentrations for
20 min, before adding 80 μM PtdIns(4,5)P2 substrate (Cayman
Chemicals) and 8 μM (<KMappATP) ATP, to give a final assay
volume of 6 μl [2% (v/v) DMSO assay final]. The assay was
allowed to proceed for 80 min at ambient temperature, before
the assay was stopped with the addition of 4 μl of kinase Glo®
Plus reagent. Plates were then covered and incubated for 20 min
before the luminescence signal was read with a PHERAstar plate
reader (BMG Labtech).
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The IP1 cell-based assay was performed using the HTRF IP-
One Tb kit (CisBio) in Greiner 384-well tissue culture-treated
white low-volume plates. NIH 3T3 cells, stably transfected using
SV40 with the PDGFRβ receptor, were cultured in DMEM, 10%
FBS, 1%GlutamaxTM and 2 ng/ml puromycin. Cells were starved
24 h before use in DMEM, 1% charcoal-stripped FBS and 1%
GlutamaxTM. After harvesting, cells were resuspended at a final
concentration of 1.25×106 cells/ml in IP1 cell stimulation buffer,
and 8 μl was dispensed into each well of the assay plate pre-dosed
with compound or DMSO. After incubation for 30 min at 37 ◦C,
cells were then stimulated with 150 nM PDGF (Sigma–Aldrich)
dispensed using an ECHO 555. A standard curve IP1 calibration
plate was prepared according to the manufacturer’s instructions.
After incubation for 30 min at 37 ◦C, cells were lysed with the
addition of 3 μl of lysis buffer with IP-One d2 (1:20 dilution), and
3 μl of lysis buffer with anti-IP-One Tb cryptate (1:20 dilution).
Plates were covered and incubated for 2 h at ambient temperature,
before a HTRF read at 615 nm and 665 nm on an EnVision plate
reader (PerkinElmer). Assay values were then normalized to the
IP1 calibration curve.
Immunoprecipitation and assay of SGK3 and SGK2
In vitro kinase activity of SGK3 and SGK2 was assayed by
measuring [γ -32P]ATP incorporation into Crosstide substrate
peptide [GRPRTSSFAEGKK]. SGK3 with a C-terminal FLAG-
tag was immunoprecipitated from doxycycline-induced U2OS
Flp/In cell lines. Immunoprecipitates were washed in sequence
with lysis buffer containing high salt concentration (500 mM
NaCl), lysis buffer and buffer A (50 mM Tris/HCl, pH 7.5, and
0.1 mM EGTA). Reactions were carried in 40 μl of total volume
containing 0.1 mM [γ -32P]ATP (400–1000 c.p.m./pmol), 10 mM
magnesium acetate and 30 μM Crosstide peptide. Reactions were
terminated by adding 10 μl of 0.1 mM EDTA and spotting 40 μl
of the reaction mixture on P81 paper which were immediately
immersed into 50 mM orthophosphoric acid. Papers were washed
several times in 50 mM orthophosphoric acid, rinsed in acetone
and air dried. Radioactivity was quantified by Cerenkov counting.
One unit of enzyme activity was defined as the amount of enzyme
that catalyses incorporation of 1 nmol of [γ -32P]ATP into the
substrate over 1 min.
Immunofluorescence and time-lapse microscopy
Cells were cultured on glass coverslips and processed for
immunocytochemistry using standard protocols. For experiments
investigating the subcellular distribution of SGK3 C-terminally
tagged GFP wild-type and mutant proteins and GFP–PHAkt cells
were fixed with 4% paraformaldehyde for 15 min at room
temperature and processed for imaging without permeabilization.
For experiments quantifying co-localization of SGK3–GFP with
EEA1 (early endosome antigen 1) and localization GFP–FYVEHrs
in response to inhibitor treatment, cells were permeabilized
via one freeze–thaw cycle in liquid nitrogen and subsequently
fixed. The following primary antibodies were used: rabbit anti-
EEA1 (1:500 dilution; Life Technologies) and mouse anti-GFP
(1:1000 dilution; Life Technologies) antibodies. Fluorophore-
conjugated secondary antibodies (Alexa Fluor® 594 and Alexa
Fluor® 488) were obtained from Life Technologies. Imaging was
conducted using a Nikon Eclipse Ti-S microscope (×40 objective)
or a Zeiss LSM710 laser scanning confocal microscope [×63
Plan-Apochromat oil immersion objective; 1.40 NA (numerical
aperture)] as described in the Figure legends. Time-lapse
microscopy was carried out on the same microscope using a
heated incubator, heated stage plate and CO2 controller (Pecon)
to maintain the cells.
Images were acquired every 0.5 min up to 60 min. Inhibitors
were added after acquiring two images, except for VPS34-IN1
that was added after the first image taken. Post-acquisition, image
analysis was conducted with Volocity 6.3 (PerkinElmer).
Lipid overlay assay
The assay was performed as described previously [33].
Briefly, 500 pmol of each lipid [Ptdins, PtdIns(3)P, PtdIns(4)P,
PtdIns(5)P, PtdIns(3,4)P2, PtdIns(4,5)P2, Ptdins(3,5)P2 and
PtdIns(3,4,5)P3] were spotted on to Hybond-C membrane (GE
Healthcare) and let dry for 1 h. The membrane was blocked
in blocking buffer (50 mM Tris/HCl, pH 7.5, 150 mM NaCl,
0.1% Tween-20 and 2 mg/ml fatty acid-free BSA) for 1 h. The
membrane was incubated overnight at 4 ◦C in a 10 nM solution
of each recombinant protein. After washing in TBST buffer
(50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20), the
signal was detected by using HRP-conjugated anti-FLAG or HRP-
conjugated anti-GST antibodies (Roche) at a 1:3000 dilution. All
lipids were purchased from Echelon and dissolved in 1:1 solution
of methanol and chloroform.
ITC (isothermal titration calorimetry)
ITC experiments were carried out on a Microcal VP-ITC. A
series of injections of peptide were made into an isolated
chamber containing the protein at a constant temperature of
30 ◦C. Heat changes within the cell were monitored during each
injection of peptide and recorded as the total heat change per
second over time. A binding isotherm was then fitted to data
and expressed as the heat change per mol of peptide against
the peptide/protein ratio. Injectant was PtdIns and PtdIns(3)P
(Echelon) dissolved in buffer (50 mM Hepes, pH 7.4, and 150 mM
NaCl). The chamber contained recombinant 3×FLAG–SGK3-
(1–162), 3×FLAG–SGK3-(1–162) R50A and 3×FLAG–SGK3
R90A in a buffer (50 mM Hepes, pH 7.4, and 150 mM NaCl).
During each experiment, 40×6 μl doses of peptide were injected
into the chamber of protein, which was stirred constantly at
300 rev./min. Each injection was followed by a 3 min period
to ensure equilibration of the solution. All experiments were
repeated and where possible using different concentrations of
separately prepared protein. Data were analysed using Origin 7.0
with the Microcal software patch installed. Each experimental
condition had a blank run with protein in the chamber replaced
with buffer. These data were then subtracted from the run with
protein present to take into account any energy of dilution or
metal/buffer reaction. A binding isotherm was then fitted to the
data using a least squares calculation to yield a χ 2 value. The
model that produced the lowest χ 2 value was taken as the best fit.
Statistical analysis
All experiments in the present study were performed at least twice
and similar results were obtained. Data were analysed using one-
way ANOVA followed by Bonferroni’s post-hoc test (P < 0.05)
using Prism software. The error bars indicate S.D.
RESULTS
VPS34-IN1 is a potent and selective inhibitor of Vps34 class III PI3K
The structure of the bipyrimidinamine VPS34-IN1 compound is
shown in Figure 1(A). This compound was originally reported in a
patent (WO 2012085815 A1). We found that VPS34-IN1 inhibited
phosphorylation of PtdIns by recombinant insect cell expressed
Vps34–Vps15 complex with an IC50 of ∼25 nM employing
both an in-house assay (Figure 1B) or using an external assay
undertaken by Life Technologies (Supplementary Figure S1).
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Figure 1 VPS34-IN1, a selective inhibitor of Vps34 kinase
(A) Chemical structure of the VPS34-IN1. (B) Insect cell expressed recombinant human Vps34–Vps15 complex was assayed by measuring phosphorylation of PtdIns in a 32P-radioactive kinase
assay in the absence or presence of the indicated concentrations of VPS34-IN1. Reactions were chromatographed on a Silica 60 TLC plate and 32P-radioactivity associated with the spot comprising
PtdIns(3)P was visualized (top panel) and quantified (bottom panel) by phosphoimager analysis on a Fujifilm Image reader FLA-2000 employing the AIDA image analysis software. Data are shown
as the mean kinase activity +− S.D. for three independent experiments, relative to DMSO-treated sample. The IC50 histogram was generated using Prism Software with non-linear regression analysis.
(C) Protein kinase profiling of the VPS34-IN1 at a single concentration of 1 μM carried out against the Dundee panel of 140 protein kinases at the International Centre for Protein Kinase Profiling.
Results for each kinase are presented as the mean kinase activity +− S.D. for an assay undertaken in triplicate relative to a control kinase assay in which the inhibitor was omitted. Abbreviations and
assay conditions used for each kinase are defined at http://www.kinase-screen.mrc.ac.uk.
To evaluate the selectivity of VPS34-IN1, we studied the effect
that this compound had on the activity of two protein kinase
panels namely the Dundee panel (140 kinases) (Figure 1C, and
Supplementary Table S1) and the ProQinase panel (300 kinases)
(Supplementary Figure S2). These data revealed that VPS34-IN1
was remarkably selective and at a concentration of 1 μM, did
not significantly inhibit the activity of any of the protein kinases
assessed.
We next evaluated VPS34-IN1 against three different lipid
kinase profiling panels namely the Dundee panel (Figure 2A,
19 lipid kinases, includes class I PI3Ks), the AstraZeneca panel
(Figure 2B, eight lipid kinases, includes class I) and ProQuinase
panel (Figure 2C and Supplementary Figure S3, 13 lipid kinases,
includes class I and class II PI3Ks). This revealed that VPS34-
IN1 did not significantly inhibit any of the lipid kinases tested
including class I (p110α, p110β p110γ and p110δ) and all
three members of the class II PI3Ks (PI3KC2α, PI3KC2β and
PI3KC2γ ) enzymes.
VPS34-IN1 inhibits PtdIns(3)P levels at endosomes in a
dose-dependent manner
The major pool of cellular PtdIns(3)P generated in cells by Vps34
accumulates on the surface of endosome membranes, which can
be visualized using a GFP-tagged probe fused to a tandem repeat
of the FYVE domain of the endocytic pathway Hrs protein
[31]. Consistent with previous work, we observed that GFP–
2×FYVEHrs when stably expressed in U2OS osteosarcoma cells
localized to discrete punctate cytoplasmic structures characteristic
of endosomes (Figure 3). Treatment with Vps34-IN1 for 1 h
induced a marked dose-dependent suppression of endosomal
localization of GFP–2×FYVEHrs with ∼80% loss observed at
1.0 μM and ∼50% loss at 0.1 μM (Figure 3). We did not observe
significant reduction in binding when employing PI3K class I
inhibitor GDC-0941.
VPS34-IN1 rapidly reduces PtdIns(3)P levels at endosomes
We also undertook a live imaging analysis monitoring the effect
of 1 μM VPS34-IN1 on localization GFP–2×FYVEHrs with time.
The data demonstrated that the effect of VPS34-IN1 in dispersing
punctate endosomal localization of GFP–2×FYVEHrs was rapid
with significant effects observed within 1 min (the earliest time-
point that can be reliably analysed) and near maximal effects
within 2 min (Figure 4A). Low levels of endosomal localization
of GFP–2×FYVEHrs were maintained for up to 60 min, the longest
time point we analysed (Figure 4). As expected treatment of U2OS
cells with 0.5 μM GDC-0941, a class I PI3K inhibitor that does
not inhibit Vps34 [34], had no effect on endosomal localization
of GFP–2×FYVEHrs even after 60 min treatment (Figure 4A).
Combination of VPS34-IN1 and GDC-0941 dispersed endosomal
localization of GFP–2×FYVEHrs similarly to VPS34-IN1 alone
c© The Authors Journal compilation c© 2014 Biochemical Society
418 R. Bago and others
Figure 2 VPS34-IN1 selectively inhibit class III PI3K
(A) Lipid kinase profiling of the VPS34-IN1 at 1 μM was carried out against a panel of 19 lipid kinases at the International Centre for Protein Kinase Profiling. (B) Summary of the measurements
of VPS34-IN1 for the indicated kinases and IP1 levels in cells (see the Materials and methods section for assay conditions). (C) Lipid kinase profiling of VPS34-IN1 inhibitor was carried out
against ProQinase panel of 13 lipid kinases. Summary of IC50 measurements for each kinase is presented in the Table. Abbreviations used for each kinase and assay conditions used are defined at
http://www.proqinase.com. Dose–response curves for data marked with an asterisk are presented in Supplementary Figure S3.
Figure 3 VPS34-IN1 reduces GFP–2×FYVEHrs probe localization on endosomes in a dose-dependent manner
U2OS cell line stably expressing GFP–2×FYVEHrs was treated with indicated concentration of VPS34-IN1 inhibitor for 1 h. The cells were permeabilized by freeze–thaw in liquid nitrogen and fixed
in 4 % paraformaldehyde. The GFP signal was enhanced by using mouse anti-GFP primary and anti-mouse Alexa Fluor® 488 secondary antibody. The top panel shows representative cell images of
GFP–2×FYVEHrs localization and the bottom panel shows corresponding DAPI staining for each condition. The histogram displays average cell fluorescence +− S.D. compared with DMSO-treated
control. Similar result was obtained in at least one other experiment. The average cell fluorescence was calculated by dividing total fluorescence of each field by the number of the cells in the
field. For each condition, ten random fields were chosen containing 20–25 cells/field. Images were taken using Nikon Eclipse Ti-S microscope using ×40 objective. Analysis was performed using
NIS-Elements BR3.1 program. Scale bar, 20 μm. *P 0.05, ***P 0.001. ns, not significant.
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Figure 4 VPS34-IN1 rapidly reduces GFP–2×FYVEHrs probe localization on endosomes
(A) The U2OS cell line stably expressing GFP–2×FYVEHrs was recorded for approximately 1 min, before adding either no inhibitor (top panel), 1 μM VPS34-IN1 (second panel), 0.5 μM GDC-0941
(third panel) or a combination of 1 μM VPS34-IN1 and 0.5 μM GDC-0941 (bottom panel). Images were taken starting at 1.5 min from the time that the inhibitor was added (the first time point
we could reliably measure) and subsequently at 0.5 min intervals up to a period of 1 h. Time-lapse microscopy was performed on Zeiss 710 microscope using ×63 objective. Similar results were
obtained in at least two separate experiments. Scale bar, 20 μm. (B) As in (A) except the U2OS cell line stably expressing GFP–PHAkt1 was starved of serum overnight and treated with either no
inhibitor (left panel), 1 μM VPS34-IN1 (middle panel) or 0.5 μM GDC-0941 (right panel) for 1 h before stimulation with IGF (100 ng/ml for 15 min). The cells were fixed with 4 % paraformaldehyde
and images were taken using Zeiss 710 microscope at ×63 objective. Representative images are shown and similar results were obtained in two experiments. Scale bar, 20 μm.
(Figure 4A). It should be noted that low levels of residual
PtdIns(3)P were still observed in cells treated with both VPS34-
IN1 and GDC-0941, which could represent PtdIns(3)P generated
through class II PI3K which was not inhibited by either inhibitor.
We also found that 1 μM VPS-34-IN1 had no impact on
the ability of IGF1 (insulin-like growth factor 1) to induce
plasma membrane recruitment of a GFP probe encompassing
the isolated PtdIns(3,4,5)P3/PtdIns(3,4)P2 binding PH domain
of Akt1 (GFP–PHAkt1) (Figure 4B). In parallel experiments
the class I PI3K GDC-0941 inhibitor blocked IGF1-induced
translocation of the GFP–PHAkt1 probe to the plasma membrane
(Figure 4B).
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Figure 5 SGK3 binds to PtdIns(3)P via its PX domain
(A) ITC was performed by gradually titrating 0.5 mM PtdIns(3)P into the reaction chamber containing wild-type 3×FLAG–SGK3-(1–162) PX domain (left panel) or mutant 3×FLAG–SGK3-(1–162)
R50A PX domain (middle panel) and 3×FLAG–SGK3-(1–162) R90A PX domain (right panel). The top panel illustrates enthalpic heat released during titration at 30◦C and the bottom panel presents
integrated binding isotherms and the best fit curves. K d are indicated on the graphs. The measurement was performed on a VP-ITC MicroCalorimeter MicroCal machine. K d were calculated using
Origin 7.0 with ITC data analysis disc program. (B) The ability of the indicated GST fusion proteins to bind various phosphoinositides was analysed. The indicated phosphoinositides (500 pmol)
were spotted on to nitrocellulose membranes, which were then incubated with 10 nM of the wild-type and indicated mutants of 3×FLAG–SGK3-(1–162) PX domain or GST-fusion PH domains
[PLCδ-(1–178), GRP1-(241–399), TAPP1-(195–315) proteins]. The membranes were washed and the PX domain protein bound to the membrane by virtue of its interaction with lipid was detected
using by using HRP-conjugated anti-FLAG antibodies (SGK3 PX domain) or anti-GST (PH domains).
PtdIns(3)P binding to PX domain localizes SGK3 to endosomes
We speculated that one downstream target of Vps34 might
comprise the serum- and glucocorticoid-induced protein kinase
SGK3, which is unique among kinases in that it possesses
an N-terminal PX domain that binds specifically to PtdIns(3)P
[35,36]. Using isothermal calorimetry, we confirmed previous
work [35,36] that the isolated PX domain of SGK3 (residues
1–162, PXSGK3) interacted with PtdIns(3)P (Kd1 of 1.8 μM
and Kd2 of 5.2 μM), but not with unphosphorylated PtdIns
(results not shown). Molecular modelling of the non-complexed
crystal structure of PXSGK3 suggested that the conserved Arg50
and Arg90 residues located within the PX domain might form
ionic interactions with the 3′-phosphate of PtdIns(3)P [37]. We
therefore mutated Arg50 or Arg90 to alanine and found that these
mutations abolished binding of PXSGK3 to PtdIns(3)P in either
ITC (Figure 5A) or protein lipid overlay binding [33] assays
(Figure 5B). We also corroborated previous work [35,36], that
PXSGK3 binds specifically to PtdIns(3)P and not to a range of
other phosphoinositides tested [PtdIns, PtdIns(4)P, PtdIns(5)P,
PtdIns(4,5)P2, PtdIns(3,4)P2 or PtdIns(3,4,5)P3] under conditions
which Grp1 PH domain interacted with PtdIns(3,4,5)P3,
the TAPP1 PH domain interacted with PtdIns(3,4)P2 and
the phospholipase Cδ PH domain bound PtdIns(4,5)P2 [33]
(Figure 5B).
PtdIns(3)P binding localizes SGK3 to early endosomes
We next analysed the cellular location in U2OS cells of full-length
wild-type SGK3 possessing a C-terminal GFP tag. This revealed
clear-cut punctate endosomal localization of wild-type SGK3
that overlapped with localization of the early endosomal EEA1
marker [38] (Figure 6A). In contrast, the non-PtdIns(3)P-binding
SGK3(R50A) or SGK3(R90A) mutants were diffusely dispersed
throughout the cytosol (Figure 6A). Using time-lapse microscopy
we also observed that treatment of cells with 1 μM VPS34-IN1
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Figure 6 PtdIns(3)P binding localizes SGK3 to endosomes
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resulted in the rapid dispersal of SGK3 from the endosomes within
1 min. In contrast, treatment with the class I PI3K inhibitor GDC-
0941 (0.5 μM) did not change significantly the SGK3 localization
on endosomes (Figure 6B). Dual treatment with VPS34-IN1 and
GDC-0941 inhibitors revealed that the effect of inhibitors on
PtdIns(3)P production was as rapid as with VPS34-IN1 alone
resulting in reduced SGK3 punctate appearance.
PtdIns(3)P binding controls SGK3 activity and hydrophobic motif
phosphorylation
SGK3, similar to many other AGC kinases including Akt
isoforms, is activated following phosphorylation of its catalytic
domain T-loop motif (Thr320) by PDK1 and its non-catalytic
C-terminal hydrophobic motif (Ser486) by mTOR [35,39,40].
Previous work with SGK1 has shown that mTORC2-mediated
phosphorylation of the hydrophobic motif markedly enhances
phosphorylation of the T-loop residue by creating a binding
motif for PDK1 [40–42]. Consistent with previous work, we
observed that full-length wild-type SGK3 when stably expressed
in U2OS cells displayed considerable kinase activity towards
the Crosstide peptide (assessed after immunoprecipitate kinase
assay) and was also significantly phosphorylated at its T-loop
and hydrophobic motifs (assessed employing phosphospecific
antibodies recognizing these sites) (Figure 7). Strikingly, the
non-PtdIns(3)P-binding SGK3(R50A) or SGK3(R90A) mutants
displayed only low kinase activity and T-loop and hydrophobic
motif phosphorylation, suggesting PtdIns(3)P binding to the
PX domain plays a critical role in enabling SGK3 to become
phosphorylated at its T-loop and hydrophobic motif and therefore
become activated (Figure 7). As expected, treatment of cells with
a selective PDK1 inhibitor (GSK2334470) [43] suppressed SGK3
activity, as well as T-loop and hydrophobic motif phosphorylation,
to near basal levels, similar to those observed following mutation
of the PX domain (Figure 7).
Class I and class III PI3K inhibitors rapidly suppress SGK3 activity
and T-loop/hydrophobic motif phosphorylation
We next treated U2OS cells stably expressing SGK3 with
increasing doses of VPS34-IN1 for 1 h and tested how this
affected SGK3 activity and T-loop phosphorylation. This revealed
that VPS34-IN1 induced a dose-dependent reduction in SGK3
activity that was maximally lowered by ∼60% at 1 μM and
∼40% at 0.1 μM (Figure 8A). The suppression of SGK3
activity induced by VPS34-IN1 treatment was accompanied
by a commensurate decrease in T-loop and hydrophobic motif
phosphorylation (Figure 8A).
We also observed that addition of the selective class I PI3K
inhibitor GDC-0941 induced a ∼40% inhibition of SGK3 activity
accompanied by a similar reduction in T-loop and hydrophobic
motif phosphorylation (Figure 8A). Moreover, a structurally
distinct selective class I PI3K inhibitor that is in clinical trials
termed BKM120 [44] induced a comparable ∼40% inhibition
of SGK3 (Figure 8B). Consistent with GDC-0941 (Figure 8A)
and BKM120 (Figure 8B) inhibiting a class I PtdIns kinase,
Figure 7 SGK3 phosphorylation and kinase activity is controlled by its
ability to bind PtdIns(3)P
(A) U2OS stably expressing wild-type or indicated mutant of full-length SGK3 with a
C-terminal FLAG-tag were treated in the absence or presence of the indicated PDK1 inhibitor
(1 μM GSK2334470) for 1 h. The cells were lysed and SGK3 immunoprecipitated with
anti-FLAG antibody. The immunoprecipitates were subjected to immunoblot analysis with the
indicated antibodies (lower panel) after being assayed for SGK3 kinase activity by measuring
phosphorylation of the Crosstide substrate peptide in the presence of 0.1 mM [γ -32P]ATP in
a 30 min reaction (upper panel). Kinase reactions are presented as means +− S.D. for triplicate
reaction. The similar result was obtained in at two separate experiments. ****P 0.0001.
they suppressed the Akt T-loop (Thr308) and hydrophobic motif
(Ser473) phosphorylation, as well as Akt substrate PRAS40
phosphorylation (Thr246), to near basal levels. At the doses used
neither GDC-0941 nor BKM120 was judged to significantly
suppress mTOR activity based on the lack of effect that these
compounds had on the phosphorylation of the 4EBP1 at sites
phosphorylated by mTORC1 (Thr37, Thr46 and Ser65) (Figure 8B).
Treatment of cells with the AZD8055 [45] mTOR inhibitor in
parallel experiments led to marked dephosphorylation of 4E-BP1
at residues phosphorylated by mTOR (Figure 8B).
Combining 1.0 μM VPS34-IN1 and 0.5 μM GDC-0941
inhibitors reduced SGK3 activity and phosphorylation by over
80% to a similar extent as observed with treatment with AZD8055
mTOR inhibitor (Figure 8A).
A time course analysis revealed that the effect of 1 μM
VPS34-IN1 on SGK3 activity and phosphorylation was extremely
rapid and activity reduced by 50% within 15 s and maximally
(A) U2OS stably expressing wild-type or indicated mutant of full-length SGK3 with a C-terminal GFP-tagged were fixed with 4 % (v/v) paraformaldehyde and GFP distribution in cell was visualized.
Images were taken using a Nicon Eclipse Ti-S microscope with ×40 objective (upper panel). SGK3 co-localization with early endosomal marker EEA1 marker was visualized using rabbit anti-EEA1
primary and anti-rabbit Alexa Fluor® 594 secondary antibody (lower panel). Pictures were taken with Zeiss 710 microscope using ×100 objective. Mander’s correlation coefficient in 112 cells was
calculated using the Volocity 6.3 program. Scale bar, 20 μm. (B) The U2OS cell line stably expressing full-length SGK3 with an C-terminal GFP-tagged were recorded for approximately 1 min, before
adding either no inhibitor (top panel), 1 μM VPS34-IN1 (second panel), 0.5 μM GDC-0941 (third panel) or a combination of 1 μM VPS34-IN1 and 0.5 μM GDC-0941 (bottom panel). Images were
taken starting at 1.5 min from the time that the inhibitor was added (the first time point we could reliably measure) and subsequently at 0.5 min intervals up to a period of 1 h. Time-lapse microscopy
was performed on Zeiss 710 microscope using ×63 objective. Representative images are shown and similar results were obtained in two experiments. Scale bar, 20 μm.
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Figure 8 Evidence that SGK3 phosphorylation and kinase activity is controlled by Vps34 and class I PI3K
(A) U2OS stably expressing wild-type or indicated mutant of full-length SGK3 with a C-terminal FLAG-tag were treated in the absence or presence of the indicated concentrations of VPS34-IN1 inhibitor
or class I PI3K inhibitor (0.5 μM GDC-0941 [34]) PDK1 inhibitor (1 μM GSK2334470 [43]), mTOR inhibitor (0.1 μM AZD8055 [45]) for 1 h. The cells were lysed and SGK3 immunoprecipitated
with anti-FLAG antibody. The immunoprecipitates were subjected to immunoblot analysis with the indicated antibodies (lower panel) after being assayed for SGK3 kinase activity by measuring
phosphorylation of the Crosstide substrate peptide in the presence of 0.1 mM [γ -32P]ATP in a 30 min reaction (upper panel). Kinase reactions are presented as means +− S.D. for triplicate reaction.
(B and C) As in (A) except cells were treated with the indicated doses of the BKM120 class I PI3K inhibitor. Similar results were obtained in at least two separate experiments for all data shown in
this Figure. ***P 0.001, **P 0.01 and *P 0.05. ns, not significant.
suppressed within 1 min (Figure 9A). In contrast, the effect of
GDC-0941 on SGK3 activity and phosphorylation was slower
with little effect observed at a 1 min time point, but activity
declining significantly thereafter with near maximal inhibition
observed after 2 min of GDC-0941 treatment (Figure 9B).
Consistent with VPS34-IN1 not supressing class I PI3Ks, we
observed that the inhibitor had no effect on Akt phosphorylation at
Ser473 and Thr308 or phosphorylation of the Akt substrate PRAS40
(Figure 8A). We also monitored NDRG1 phosphorylation at
Thr346 a site that can be phosphorylated by SGK or Akt isoforms
[46]. In U2OS cells, as observed in some other cell types [46],
it seems that phosphorylation of NDRG1 is mediated mainly
through Akt as its phosphorylation is significantly suppressed
by GDC-0941, but only affected moderately by VPS34-IN1
(Figure 8). Moreover, in agreement with the notion that the
ability of SGK3 to be inhibited by VPS34-IN1 is dependent on
its PtdIns(3)P-binding PX domain, we observed that VPS34-IN1
did not inhibit the activity of SGK2 isoform that does not possess
a PX domain (Figure 9C).
DISCUSSION
VPS34-IN1 is the first highly selective cell permeable Vps34
inhibitor to be reported. Previously utilized Vps34 inhibitors
have included wortmannin [47], LY294002 [48], 3-methyladenine
[47], KU55933 [49,50] and Go¨6976 [50] that are not
selective inhibitors. Wortmannin and LY294002 when used at
concentrations that inhibit Vps34 also suppress class I PI3Ks
and several kinases that belong to the PI3K-related kinase
(mTOR and DNA-dependent protein kinase) in addition to many
other protein and lipid kinases [51–53]. KU55933 potently
inhibits the DNA damage repair ATM protein kinase and to
our knowledge has not been thoroughly profiled against a panel
of lipid kinases including class I and class II PI3Ks so the
off-target effects of this compound are unknown. The protein
kinase C inhibitor Go¨6976 is poorly selective inhibiting many
protein kinases (http://www.kinase-screen.mrc.ac.uk/screening-
compounds/341062). To our knowledge extensive protein
and lipid kinase profiling has not been undertaken for 3-
methyladenine, but in our judgment this simple adenine derivative
is unlikely to comprise a selective Vps34 inhibitor. In contrast, the
selectivity data for VPS34-IN1 indicates that it is a remarkably
selective Vps34 inhibitor. We have profiled VPS34-IN1 against
340 unique protein kinases (Figure 1 and Supplementary Figure
S2) and 25 lipid kinases that include all four members of the class
I PI3K and three members of the class II PI3Ks (Figure 2, and
Supplementary Figures S1 and S3). We have found that, other
than Vps34, no kinase is markedly inhibited at a concentration
of 1 μM, which is 40-fold higher than the IC50 value that
VPS34-IN1 inhibits Vps34 and the highest concentration of
compound we have used in cells. It is reassuring that VPS34-
IN1 does not inhibit any of the three members of the class II
PI3Ks, as these poorly understood enzymes, which are similar to
Vps34, also generate PtdIns(3)P. This provides confidence that
the impact that VPS34-IN1 has on endosomal PtdIns(3)P levels
and SGK3 activity in vivo is indeed due to inhibition of PtdIns(3)P
generated through the action of Vps34.
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Figure 9 Class I and class III PI3K inhibitors rapidly inactivate SGK3 and evidence that SGK2 is not regulated by Vps34
(A and B) U2OS stably expressing wild-type full-length SGK3 with a C-terminal FLAG-tag were treated in the absence or presence of the 1 μM VPS34-IN1 (A) or 0.5 μM GDC-0941 (B) for the
indicated times. The cells were lysed and SGK3 immunoprecipitated with anti-FLAG antibody. The immunoprecipitates were subjected to immunoblot analysis with the indicated antibodies (top
panel) after being assayed for SGK3 kinase activity by measuring phosphorylation of the Crosstide substrate peptide in the presence of 0.1 mM [γ -32P]ATP in a 30 min reaction (bottom panel).
Kinase reactions are presented as means +− S.D. for triplicate reaction. (C) As above except U2OS stably expressing wild-type full-length SGK2 with a C-terminal FLAG-tag were treated in the absence
or presence of the indicated inhibitors for 1 h. Similar results was obtained in at least two separate experiments for all data shown in this Figure. ***P 0.001, **P 0.01 and *P 0.05. ns, not
significant.
The evidence that VPS34-IN1 suppresses Vps34 activity in vivo
is supported by the observation that treatment of cells with
VPS34-IN1 induces a strikingly rapid dose-dependent dispersal
of the localization of the PtdIns(3)P-binding GFP–2×FYVEHrs
from endosomal membranes (Figures 3, 4 and 6), where
PtdIns(3)P is produced by Vps34 resides [31,54]. Consistent
with the in vitro IC50 of VPS34-IN1 for Vps34 being 25 nM
(Figure 1B and Supplementary Figure S1), treatment of cells with
0.01 μM VPS34-IN1 induced a weak effect on GFP–2×FYVEHrs
localization, whereas 0.1 μM and 1 μM VPS34-IN1 induced
∼50% and ∼80% respectively dispersal of GFP–2×FYVEHrs
endosomal localization (Figure 7). The effect of VPS34-IN1 in
dispersing the endosome-localized GFP–2×FYVEHrs (Figure 4)
and GFP–SGK3 (Figure 6) is rapid and essentially complete
within 60–120 s, the earliest time point we can reliably assess
in live cell imaging experiments. In future work it would be
interesting to explore whether there is an interplay between class II
and class III PI3Ks and whether inhibition of Vps34 results in the
activation of a class II PI3K-driven compensatory mechanism to
produce PtdIns(3)P. Moreover, we observed a marked reduction
in SGK3 activity and phosphorylation within 15 s treatment
with VPS34-IN1 which was nearly maximal by 30 s. These
observations are consistent with previous work showing that
the localization of GFP–2×FYVEHrs at the endosome is highly
dynamic and responsive to inhibition of Vps34 [55,56]. It has
been argued that the relatively low affinity of PX and FYVE
domains for PtdIns(3)P coupled with high myotubularin PtdIns
3-phosphatase activity accounts for rapid and highly dynamic
localization and response [25,29]. Our results highlight that full-
length SGK3 is similarly dynamic and responsive to changes
PtdIns(3)P as the well-characterized GFP–2×FYVEHrs probe.
The finding that VPS34-IN1 does not inhibit the localization
of the PtdIns(3,4,5)P3/PtdIns(3,4)P2 binding GFP–PHAkt1 to the
plasma membrane or inhibit Akt phosphorylation at Thr308 or
Ser473 establishes that VPS34-IN1 is not suppressing the activity
of class I PI3Ks in vivo, consistent with the in vitro lipid kinase
profiling data. The finding that VPS34-IN1 does not suppress
activity of SGK2 that does not possess a PtdIns(3)P-binding PX
domain (Figure 9C) is also consistent with the notion that the
ability of VPS34-IN1 to suppress SGK3 is dependent on its ability
to bind PtdIns(3)P.
SGK3 was first identified as a novel isoform of SGK1 [39]
that played a role in enabling the IL (interleukin)-3-dependent
survival of haemopoietic cells [57]. Subsequent studies revealed
that SGK3 possesses a PtdIns(3)P-binding N-terminal PX domain
[30,35,36]. To our knowledge SGK3 is unique among kinases
in possessing a PtdIns(3)P-binding domain. Consistent with
previous work [36], we show that endosomal localization, as well
as SGK3 activity and phosphorylation of regulatory T-loop and
hydrophobic motif, is markedly suppressed following mutation
of critical PtdIns(3)P-binding PX domain residues. Moreover,
inhibiting SGK3 binding to the endosomes by treating cells
with VPS34-IN1 induced a rapid 50–60% decrease in SGK3
activity accompanied by a commensurate decrease in the T-
loop and hydrophobic motif phosphorylation. In future work
it would be important to explore the mechanism by which
PtdIns(3)P binding and endosomal localization controls SGK3
activity by regulating phosphorylation of its T-loop by PDK1
and hydrophobic motif by mTOR. It would be interesting to
explore whether PtdIns(3)P binding induces a conformational
change in SGK3 promoting phosphorylation by PDK1 and/or
mTOR. An analogous mechanism operates for Akt isoforms,
in which interaction of the PH domains of these kinases with
PtdIns(3,4,5)P3/PtdIns(3,4)P2 at the plasma membrane induces a
conformational change that markedly enhances phosphorylation
and activation by PDK1 [11,12,58,59]. It is also possible that
c© The Authors Journal compilation c© 2014 Biochemical Society
Vps34 controls SGK3 activity 425
Figure 10 Model of how SGK3 is regulated by two distinct pools of PtdIns(3)P
Our data suggest that SGK3 is controlled by two pools of PtdIns(3)P. One pool is produced via phosphorylation of PtdIns by class III PI3K termed Vps34 at the endosome and the other pool of
PtdIns(3)P is generated as a result of dephosphorylation of PtdIns(3,4,5)P3 to PtdIns(3)P through the sequential actions of SHIP1/2 and INPP4B PtdIns phosphatases. Our findings suggest that
binding of PtdIns(3)P to the PX domain triggers SGK3 activation by promoting phosphorylation of the T-loop by PDK1 and the hydrophobic motif by mTOR. Further work is required to understand
how binding of PtdIns(3)P promotes phosphorylation of SGK3 by PDK1 and mTOR.
PtdIns(3)P binding serves to anchor SGK3 to the endosome, as
well as other membranes where a pool of PDK1 and mTOR
reside, and this increases the efficiency by which these enzymes
are brought together on a two-dimensional membrane surface.
Despite mutations inhibiting PtdIns(3)P binding suppressing
SGK3 activity by over 90%, and VPS34-IN1 treatment dispersing
the vast majority of GFP–2×FYVEHrs and GFP–SGK3 from
the endosome, we find that VPS34-IN1 only partially reduced
SGK3 activity by 50–60%. Consistent with this, a previous
study has found that knockout of Vps34 in mouse embryonic
fibroblasts resulted in ∼60% loss of PtdIns(3)P levels [60],
which correlates with the inhibition of SGK3 activity observed in
U2OS cells treated with VPS34-IN1. The activity of SGK3 that
remains following VPS34-IN1 treatment is likely to be controlled
by additional pool(s) of PtdIns(3)P generated independently
of Vps34 that are able to recruit SGK3 and hence promote
activation via mTOR and PDK1. Previous work has revealed
that a pool of PtdIns(3)P can be generated in vivo through
the dephosphorylation of PtdIns(3,4,5)P3 via sequential actions
of the PtdIns 5-phosphatases (SHIP1/2) [17] and the PtdIns 4-
phosphatase (INPP4B) [18]. PtdIns(3)P produced through this
route is then rapidly dephosphorylated to PtdIns by a family
of myotubularin PtdIns 3-phosphatases [19]. Our finding that
treatment of cells with structurally diverse class I selective
PI3K inhibitors (GDC-0941 [34] and BKM120 [44]) that do
not inhibit Vps34 induce a ∼40% reduction in SGK3 activity
at doses that suppress Akt activity significantly (Figure 8)
suggests that PtdIns(3)P generated through dephosphorylation
of PtdIns(3,4,5)P3 could be controlling SGK3. However, we
cannot rule out that the effect of GDC-0941 and BKM120 on
SGK3 activity in these studies is not at least partially mediated
through the ability of these inhibitors to suppress the activity of
mTORC2, which is potentially also regulated by class I PI3K [61]
(Figure 10).
It is also interesting to note that the impact of GDC-0941
on SGK3 activity is slower than that observed for VPS34-IN1
(compare Figure 9A with 9B), which may be consistent with the
several steps between activation of class I PI3K and PtdIns(3)P.
The observation that combining VPS34-IN1 and GDC-0941
reduces SGK3 activity by 80–90% comparable with the effect
of mTOR inhibitors is consistent with the notion that the class I
and class III PI3K controlled pools of PtdIns(3)P are the key in
controlling SGK3 (Figure 10).
In future work it would also be interesting to explore whether
residual SGK3 kinase activity (Figure 8A) and the presence of low
levels of GFP–2×FYVEHrs probe and GFP–SGK3 still present on
endosomes after dual treatment with class I and class III PI3K
inhibitors are due to pools of PtdIns(3)P generated by the poorly
characterized class II PI3Ks. Previous work has suggested that
class II PI3Ks play a role in intracellular vesicular trafficking as
the kinases were found to reside on endosomes, clathrin-coated
vesicles and trans-Golgi network [62,63].
Further work is required to pinpoint the location of the class
I PI3K-controlled PtdIns(3)P pool in cells. We do not see a
marked localization of GFP–2×FYVEHrs or GFP–SGK3 at the
plasma membrane where the class I PI3K controlled the pool
of PtdIns(3)P might be expected to reside. However, PtdIns(3)P
at the plasma membrane may be much more dispersed than at
the endosome membrane, where PtdIns(3)P levels are very high,
thereby making GFP–2×FYVEHrs or GFP–SGK3 localization at
the plasma membrane harder to visualize.
There is increasing interest in understanding the physiological
roles that Vps34 as well as SGK3 play. Our data indicate that
VPS34-IN1 will be a useful tool to probe the cellular functions of
Vps34 and that monitoring SGK3 activity and/or phosphorylation
could serve as a biomarker for Vps34 activity in vivo. There
is also increasing evidence that a significant number of human
tumours that are insensitive to class I PI3K inhibition display
elevated levels of SGK3 and that this plays an important role in
driving survival and proliferation [64–68]. In future work it will
be important to learn more about the roles that SGK3 plays at the
endosome and potentially other membranes. It will be important to
identify physiological substrates for SGK3 and explore whether
inhibiting Vps34 or SGK3 could be deployed as a therapeutic
strategy to treat tumour cells displaying elevated SGK3 activity.
Finally, our data indicate that combining GDC-0941 and VPS34-
IN1 might be used as a strategy to inhibit pools of PtdIns(3)P
generated by class I and III PI3Ks that would better allow the
study of the roles and regulation of the elusive class II PI3Ks to
be visualized.
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